Statement of deviation(s) or variation(s) under Reg. 32

Date: 07-11-2026 National Stock Exchange of India Limited BSE Limited Exchange Plaza, C-1, Block G Listing Department Bandra Kurla Complex, Dalal Street, Bandra East, Mumbai-400051 Mumbai-400001 Scrip Code: MUKKA Scrip Code: 544135 Dear Sir/Madam, Subject: Statement of deviation(s) or variation(s) of funds raised through Preferential Issue of Warrants for the quarter ended 30th September 2026. Pursuant to Regulation 32(1) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the statement of deviation(s) or variation(s) in utilization of funds raised through preferential issue of warrants for the quarter ended 30th September 2026, duly reviewed by the Audit Committee at its meeting held today i.e., Saturday, 7th November 2026, in the format prescribed by SEBI vide Circular No. CIR/CFD/CMD1/162/2019 dated December 24, 2019. Further, we confirm that there has been no deviation(s) or variation(s) in the utilization of proceeds of the preferential issue. This is for your information and records. Thank you, For Mukka Proteins Limited Mehaboobsab Mahmadgous Chalyal Company Secretary & Compliance Officer Membership No.: A67502 Encl: as above. Statement of deviation or variation in utilisation of funds raised Name of listed entity Mukka Proteins Limited Mode of Fund Raising Preferential Issues Date of Raising Funds Date of allotment - 09/09/2026 Amount Raised Rs. 47,00,00,000/- Report filed for Quarter ended 30th September 2026 Monitoring Agency Not Applicable Monitoring Agency Name, if applicable Not Applicable Is there a Deviation / Variation in use of funds raised No If yes, whether the same is pursuant to change in Not Applicable terms of a contract or objects, which was approved by the shareholders If Yes, Date of shareholder Approval Not Applicable Explanation for the Deviation / Variation Not Applicable Comments of the Audit Committee after review Not Applicable Comments of the auditors, if any Not Applicable Objects for which funds have been raised and where there has been a deviation, in the following table: Original Object Modi Original Modifie Funds Amount of Remarks fied Allocation (in d Utilised (in Deviation/Variatio if any Obje Rs.) allocatio Rs.) n for the quarter ct, if n, if any according to any applicable object Funding NA 35,00,00,000 NA 11,75,00,000 - - working capital requirements of our Company Funding NA 5,00,00,000 NA - - - business expansion plans and Supporting growth initiatives General NA 7,00,00,000 NA - - - corporate purposes Deviation or variation could mean: (a) Deviation in the objects or purposes for which the funds have been raised or (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or (c) Change in terms of a contract referred to in the fund-raising document i.e. prospectus, letter of offer, etc. For Mukka Proteins Limited Kalandan Mohammed Haris Managing Director & CEO DIN: 03020471